OncoMatch

OncoMatch/Clinical Trials/NCT06838208

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Is NCT06838208 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tislelizumab, Carboplatin /Cisplatin, Etoposide for extensive-stage small cell lung cancer (es-sclc).

Phase 2RecruitingAnhui Provincial Cancer HospitalNCT06838208Data as of May 2026

Treatment: Tislelizumab, Carboplatin /Cisplatin, Etoposide — To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Disease stage

Required: Stage IV

Histologically or cytologically confirmed ES-SCLC

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: anti-PD-1 therapy

Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody

Cannot have received: anti-PD-L1 therapy

Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody

Cannot have received: anti-CTLA-4 therapy

Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody

Lab requirements

Blood counts

adequate hematologic function

Kidney function

adequate end organ function

Liver function

adequate end organ function

Adequate hematologic and end organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify